Get access

Soya phospholipid complex of mangiferin enhances its hepatoprotectivity by improving its bioavailability and pharmacokinetics

Authors

  • Sauvik Bhattacharyya,

    1. Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, India
    Search for more papers by this author
  • Sk Milan Ahmmed,

    1. Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, India
    Search for more papers by this author
  • Bishnu Pada Saha,

    1. Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, India
    Search for more papers by this author
  • Pulok K Mukherjee

    Corresponding author
    1. Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, India
    • Correspondence to: Pulok K Mukherjee, Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata 700032, India. E-mail: naturalproductm@gmail.com

    Search for more papers by this author

Abstract

BACKGROUND

Mangiferin is a xanthonoid present in Mangifera indica. It has been reported for a variety of pharmacological activities, including hepatoprotection. However, the major disadvantage of mangiferin is its reduced biological activity due to poor absorption, low bioavailability and rapid elimination from the body after administration. The aim of this study was to prepare a phospholipid complex of mangiferin to overcome these limitations and to investigate the impact of the complex on hepatoprotective activity and bioavailability.

RESULTS

The results showed that the complex has an enhanced hepatoprotective and in vivo antioxidant activity as compared to pure mangiferin at the same dose level (30 and 60 mg kg−1). The complex restored the levels of serum hepatic marker enzymes and liver antioxidant enzymes with respect to carbon tetrachloride-treated animals. The complex also increased the bioavailability of mangiferin in rat serum by 9.75-fold compared to pure mangiferin at the same dose level and enhanced the elimination half-life (t1/2 el) from 1.71 ± 0.12 h−1 to 3.52 ± 0.27 h−1.

CONCLUSION

The results suggested that the complexation of mangiferin with soya phospholipid enhanced the hepatoprotection and in vivo antioxidant activity, which may be due to the improved bioavailability and pharmacokinetics of mangiferin in rat serum. © 2013 Society of Chemical Industry

Ancillary